Head‐to‐head comparison of TKI and CPI first‐line treatment strategies in advanced renal cell carcinoma—Real‐world data from the German research platform CARAT
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70211 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Peter J Goebell und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Erlangen, Erlangen, Germany. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Protein Kinase Inhibitors, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MSD Sharp & Dohme GmbH, IPSEN PHARMA GmbH, EUSA Pharma GmbH.
Abstract (Originalsprache)
The combination of two immune checkpoint inhibitors (CPI) or a CPI with a tyrosine kinase inhibitor (TKI) has expanded the therapeutic options for advanced/metastatic renal cell carcinoma (aRCC) beyond TKI monotherapy. In the absence of head‐to‐head randomized trials comparing these strategies, we estimate their real‐world effectiveness by emulating a hypothetical randomized trial. A total of 936 patients with aRCC from the prospective, observational, multicenter clinical registry CARAT (NCT03374267) starting first‐line treatment after January 15, 2019, were included. Inverse probability of treatment weighting (IPTW) was used to compare first‐line CPI + TKI ( n = 447), CPI + CPI ( n = 257), and TKI monotherapy ( n = 166). Real‐world progression‐free survival (rwPFS), overall survival (OS), and time‐to‐deterioration (TTD) of health‐related quality of life (HRQoL) were analyzed, also stratified by patients' prognostic risk according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model. IPTW‐adjusted median rwPFS and OS independent of IMDC risk were 12.3 [10.4–15.6] and 29.0 months [25.6–36.3] for TKI + CPI, 8.3 [6.5–10.9] and 21.9 months [16.3–34.5] for CPI + CPI, and 8.5 [6.4–10.0] and 31.7 months [21.0–40.0] for TKI monotherapy. Compared to CPI + TKI, survival tended to be worse for CPI + CPI (rwPFS: hazard ratio (HR) 1.25 [1.00–1.58]; OS: HR 1.25 [0.95, 1.63]). This finding was more pronounced for rwPFS in patients at intermediate risk. Median TTD of HRQoL did not substantially differ between the strategies. Despite the lack of statistically significant HR differences in rwPFS and OS, there was a trend toward superior survival with first‐line CPI + TKI compared to CPI + CPI. TKI monotherapy may remain a viable first‐line treatment option in selected patient populations. Further analyses, preferentially randomized clinical trials, are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University Hospital Erlangen, Erlangen, Germany.
- Department of Urology, University Hospital Muenster, Münster, Germany.
- Praxis für Hämatologie und Internistische Onkologie, Ratingen, Germany.
- Department for Internal Medicine (Tumour Research) and Department for Urology, West German Cancer Center, University Hospital Essen, Essen, Germany.
- Onkologie UnterEms, Leer, Germany.
- Onkologische Schwerpunktpraxis, Hannover, Germany.
ORCID-Profile: Peter J Goebell, Michael Staehler
Förderung
- MSD Sharp & Dohme GmbH
- IPSEN PHARMA GmbH
- EUSA Pharma GmbH
- Eisai GmbH
- MSD Sharp and Dohme
Zitieren
APA
Goebell, P. J., Bögemann, M., Nusch, A., Grünwald, V., Müller, L., von der Heyde, E., Martens, U. M., Lennartz, C., Koska, M., Potthoff, K., Kaiser-Osterhues, A., Grüllich, C., Staehler, M., Jänicke, M., Marschner, D., & CARAT Registry Group (2026). Head‐to‐head comparison of TKI and CPI first‐line treatment strategies in advanced renal cell carcinoma—Real‐world data from the German research platform CARAT. International Journal of Cancer. https://doi.org/10.1002/ijc.70211
Vancouver
Goebell PJ, Bögemann M, Nusch A, Grünwald V, Müller L, von der Heyde E, et al. Head‐to‐head comparison of TKI and CPI first‐line treatment strategies in advanced renal cell carcinoma—Real‐world data from the German research platform CARAT. International Journal of Cancer. 2026. doi:10.1002/ijc.70211
BibTeX
@article{Goebell2026,
author = {Goebell, Peter J and Bögemann, Martin and Nusch, Arnd and Grünwald, Viktor and Müller, Lothar and von der Heyde, Eyck and Martens, Uwe M and Lennartz, Carolin and Koska, Michaela and Potthoff, Karin and Kaiser-Osterhues, Anja and Grüllich, Carsten and Staehler, Michael and Jänicke, Martina and Marschner, Dominik and CARAT Registry Group, CARAT Registry Group},
title = {Head‐to‐head comparison of TKI and CPI first‐line treatment strategies in advanced renal cell carcinoma—Real‐world data from the German research platform CARAT},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70211}
}
EUVIMED